Session Information
Date: Wednesday, June 7, 2017
Session Title: Parkinson's Disease: Genetics
Session Time: 1:15pm-2:45pm
Location: Exhibit Hall C
Objective: To identify genetic risk factors for developing levodopa-induced dyskinesias (LID) in patients with Parkinson’s disease (PD).
Background: LID are common complications in PD, but there are conflicting data about genetic risk factors associated with its onset.
Methods: A cross-sectional study was conducted with epidemiological and clinical data from Brazilian PD patients enrolled from two centers as part of the Latin American Research consortium on the Genetics of PD (LARGE-PD). All PD patients were submitted to neurological examinations and semi-structured interviews performed by a neurologist with experience on Movement Disorders. Presence of LID was confirmed if UPDRS Part IV had a score ≥ 1 on item 32. Based on previous studies, we chose eight Single Nucleotide Polymorphisms (SNP) in the following genes: COMT, MAOB, ANKK1, DRD3, DAT1, BDNF, ADORA2A and NOS1. Genotyping was performed using TaqMan SNP genotyping assays. Association between SNPs and LID was tested using multivariate logistic regression under an additive model adjusting for sex, age at onset of PD and levodopa therapy duration.
Results: 186 Brazilian PD patients were enrolled (males – 58%; mean age 60 years). Of these patients, 91 (48.9%) presented LID. Only MAOB SNP rs1799836 was associated with LID, with the A allele increasing the risk of developing LIDs (OR 1.51, CI95% 1.00-2.28; p = 0.05). However, when analyzed independently in male and females (MAOB gene is located in chromosome X), these differences were not significant.
Conclusions: MAOB SNP rs1799836 is a probable genetic risk factor for LID although further studies in larger samples are required to explore the influence of MAOB polymorphisms on LID.
References: 1) Hao H, Shao M, An J, Chen C, Feng X, Xie S, Gu Z, Chan P. Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in Parkinson’s disease in a Chinese population. Parkinsonism Relat Disord. 2014 Oct;20(10):1041-5.
2) Lee JY, Cho J, Lee EK, Park SS, Jeon BS. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson’s disease. Mov Disord. 2011 Jan;26(1):73-9.
To cite this abstract in AMA style:
B. Santos-Lobato, M. Capelari, N. Novaretti, Â. Vieira, V. Borges, H. Ferraz, I. Mata, C. Zabetian, V. Tumas. Association of Single Nucleotide Polymorphism in MAOB and Risk of Levodopa-Induced Dyskinesias in Parkinson’s Disease [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/association-of-single-nucleotide-polymorphism-in-maob-and-risk-of-levodopa-induced-dyskinesias-in-parkinsons-disease/. Accessed June 14, 2025.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/association-of-single-nucleotide-polymorphism-in-maob-and-risk-of-levodopa-induced-dyskinesias-in-parkinsons-disease/